Phase I/II Study of the ILB-3101 in Patients With Advanced Solid Tumors
Latest Information Update: 11 Dec 2024
At a glance
- Drugs ILB 3101 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Innolake Biopharm
Most Recent Events
- 11 Nov 2024 Status changed from not yet recruiting to recruiting.
- 27 May 2024 New trial record